GlassScriptPhysician profile
Loring B Jacobs
NPI 1467525055
$6,507.24
in general payments reported to CMS, 2019-2025
45 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $695 · 2021: $684 · 2022: $618 · 2023: $945 · 2024: $1,400 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.19 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,342.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $940.16 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Medtronic Vascular, INC. | $486.44 | 2020 | |
| Amgen INC. | $388.58 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $314.34 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $280.65 | 2019-2025 | |
| Abbvie INC. | $266.34 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.60 | 2024-2025 | |
| Abiomed | $239.20 | 2024-2025 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.28 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $217.77 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $202.61 | 2022-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.73 | 2019-2022 | |
| Exact Sciences Corporation | $112.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $107.41 | 2020-2024 | Nexletol |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $94.34 | 2021-2025 | Venaseal |
| Abbott Laboratories | $72.69 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $71.80 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $64.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.62 | 2022 | |
| Merck Sharp & Dohme LLC | $57.77 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $45.23 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $44.40 | 2019-2021 | |
| Horizon Therapeutics Plc | $44.20 | 2019-2020 | |
| Genentech USA, INC. | $38.97 | 2021 | |
| Mylan Specialty L.P. | $38.32 | 2019 | |
| Boston Scientific Corporation | $30.40 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $28.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.52 | 2024 | Voquezna |
| Corcept Therapeutics | $24.03 | 2024 | Korlym |
| Sobi, INC | $23.36 | 2022 | |
| Almatica Pharma LLC | $20.01 | 2023 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $19.21 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.82 | 2023 | Nuedexta |
| Kaleo, INC. | $18.80 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.40 | 2025 | Keveyis |
| Idorsia Pharmaceuticals US INC | $16.47 | 2023 | Quviviq |
| Dexcom, INC. | $15.80 | 2025 | Dexcom G6 Transmitter |
| Inogen, INC. | $15.74 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Seqirus USA INC | $15.63 | 2025 | Fluad, Flucelvax |
| Eisai INC. | $14.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.99 | 2020 | |
| Ethicon US, LLC | $12.95 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.76 | 2019 | |
| Optos, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loring Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.